No Sanctions For GSK, But Both Sides Told To 'Dial It Back'

By Chris Villani · February 20, 2020, 3:05 PM EST

GlaxoSmithKline will not face sanctions for a call to the U.S. Food and Drug Administration tied to multidistrict litigation over whether its anti-nausea medication Zofran causes birth defects, a Boston federal...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation

Case Number

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

October 13, 2015

Recent Articles By Chris

November 13, 2024
Mass. AG Ready To Reprise Office's Role As Trump Foil
August 12, 2024
Big Tobacco To Pay $600M In 'Historic' Mass. Deal
July 23, 2024
'Surface Water' Stumps Mass. Justices In Loss For Insurers
July 12, 2024
Feds Say Fake Gunshot Wounds Part Of $1M Fraud Scheme
March 01, 2024
GSK, Shook Hardy Can Recover Costs After Zofran MDL Win
February 26, 2024
Teva Tells 1st Circ. Feds Must Clear High Bar In FCA Case
February 20, 2024
Justices Decline Malpractice Dispute Over $6M Settlement
December 21, 2023
The 5 Biggest First Circuit Rulings Of 2023
December 20, 2023
No Discovery In Regeneron FCA Case Until 1st Circ. Rules
November 21, 2023
Ex-Aegerion Rep Cops To Fraud, Avoiding Trial Redo